MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.  The company was founded in 2012 and is headquartered in Brisbane, California.

MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.

MyoKardia Begins Dosing in Phase I Study on Heart Candidate

Topline Results Expected in Mid-2020 Topline Results Expected in Mid-2020

MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy

MyoKardia (MYOK) CEO Tassos Gianakakos on Q2 2019 Results - Earnings Call Transcript

MyoKardia (MYOK) delivered earnings and revenue surprises of -5.06% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MyoKardia (MYOK) Reports Q2 Loss, Lags Revenue Estimates

MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q1 2019 Results - Earnings Call Transcript

MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for MyoKardia Stock (MYOK)